SNF2 related chromatin remodeling annealing helicase 1Genealiases: HARP · HHARP
Q-omics provides the consensus-scored SMARCAL1 profile across patient tissues and cancer cell-line models. SMARCAL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMARCAL1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SMARCAL1 RNA expression shows 19,830 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where SMARCAL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMARCAL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMARCAL1 survival associations across molecular data types. SMARCAL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMARCAL1 RNA expression–survival associations across cancer types. High SMARCAL1 expression shows unfavorable associations in ACC, MESO, LIHC, KIRP and LGG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMARCAL1 RNA expression.
This table summarizes SMARCAL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMARCAL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMARCAL1 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, COAD and KIRP. The KIRC box plot shows higher SMARCAL1 RNA expression in tumor versus normal tissue (log2 FC = +0.656, t-test p < 0.001).
This table shows molecular features associated with SMARCAL1 in patient tissues and cancer cell lines. In patient samples, SMARCAL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMARCAL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
